BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 2889299)

  • 21. Omeprazole. An updated review of its pharmacology and therapeutic use in acid-related disorders.
    McTavish D; Buckley MM; Heel RC
    Drugs; 1991 Jul; 42(1):138-70. PubMed ID: 1718683
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Omeprazole in Zollinger-Ellison syndrome. Effects of a single dose and of long-term treatment in patients resistant to histamine H2-receptor antagonists.
    Lambers CB; Lind T; Moberg S; Jansen JB; Olbe L
    N Engl J Med; 1984 Mar; 310(12):758-61. PubMed ID: 6142418
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drug therapy of peptic ulcer disease.
    Ching CK; Lam SK
    Br J Hosp Med; 1995 Jul 12-Aug 15; 54(2-3):101-6. PubMed ID: 7551483
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Omeprazole in acute and long-term treatment of Asian patients with peptic ulcer refractory to H2-antagonists.
    Chelvam P; Wong EC
    J Gastroenterol Hepatol; 1989; 4 Suppl 2():75-81. PubMed ID: 2577478
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacological and pharmacodynamic essentials of H(2)-receptor antagonists and proton pump inhibitors for the practising physician.
    Huang JQ; Hunt RH
    Best Pract Res Clin Gastroenterol; 2001 Jun; 15(3):355-70. PubMed ID: 11403532
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Lansoprazole--profile of a new proton pump inhibitor].
    Seifert E
    Leber Magen Darm; 1994 Mar; 24(2):66-8, 71. PubMed ID: 8196467
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Omeprazole in the treatment of Zollinger-Ellison syndrome and histamine H2-antagonist refractory ulcers.
    Meijer JL; Jansen JB; Lamers CB
    Digestion; 1989; 44 Suppl 1():31-9. PubMed ID: 2575060
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lansoprazole heals erosive reflux esophagitis resistant to histamine H2-receptor antagonist therapy.
    Sontag SJ; Kogut DG; Fleischmann R; Campbell DR; Richter J; Robinson M; McFarland M; Sabesin S; Lehman GA; Castell D
    Am J Gastroenterol; 1997 Mar; 92(3):429-37. PubMed ID: 9068463
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of refractory peptic ulcer with omeprazole or continued H2 receptor antagonists: a controlled clinical trial.
    Bardhan KD; Naesdal J; Bianchi Porro G; Petrillo M; Lazzaroni M; Hinchliffe RF; Thompson M; Morris P; Daly MJ; Carroll NJ
    Gut; 1991 Apr; 32(4):435-8. PubMed ID: 1673953
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Omeprazole].
    Isal JP
    Gastroenterol Clin Biol; 1987 Nov; 11(11):768-80. PubMed ID: 3322924
    [No Abstract]   [Full Text] [Related]  

  • 31. [Indications and use of omeprazole in esophago-gastro-duodenal diseases].
    Martín de Argila C; Boixeda de Miquel D; Moreira Vicente V; García Plaza A
    Rev Clin Esp; 1999 Nov; 199(11):729-39. PubMed ID: 10638238
    [No Abstract]   [Full Text] [Related]  

  • 32. Clinical perspectives of drugs inhibiting acid secretion--H+K+-ATPase inhibitors.
    Walan A
    Scand J Gastroenterol Suppl; 1986; 125():50-4. PubMed ID: 3029857
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Omeprazole versus high-dose ranitidine in mild gastroesophageal reflux disease: short- and long-term treatment. The Dutch Reflux Study Group.
    Festen HP; Schenk E; Tan G; Snel P; Nelis F
    Am J Gastroenterol; 1999 Apr; 94(4):931-6. PubMed ID: 10201459
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Histamine H2 receptor antagonist-refractory oesophagitis: the efficacy of long-term omeprazole maintenance treatment.
    Bardhan KD; Cherian P; Jones RB; Vaishnavi A; Manek S; Bishop A; Polak J; Brooks A; Morris P; Thompson M; D'Silva J; Parkin S; Patterson J; Gillon KR
    Ital J Gastroenterol Hepatol; 1997 Dec; 29(6):515-9. PubMed ID: 9513825
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Progress with proton pump inhibitors in acid peptic disease: treatment of duodenal and gastric ulcer.
    Florent C
    Clin Ther; 1993; 15 Suppl B():14-21. PubMed ID: 7911399
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Is strong inhibition of gastric acid in the treatment of peptic ulcer sensible?].
    de Bruijne JW; Lamers CB
    Ned Tijdschr Geneeskd; 1989 Apr; 133(13):657-62. PubMed ID: 2566125
    [No Abstract]   [Full Text] [Related]  

  • 37. [The present state of knowledge on the treatment of peptic diseases with cimetidine].
    Romankiewicz JA; Reidenberg MM
    Internist (Berl); 1981 Dec; 22(12):762-6. PubMed ID: 6797984
    [No Abstract]   [Full Text] [Related]  

  • 38. Duodenal ulcer and gastroesophageal reflux disease today: long-term therapy--a sideways glance.
    Bardhan KD
    Yale J Biol Med; 1996; 69(3):211-24. PubMed ID: 9165690
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Conservative treatment of florid peptic esophageal stenosis. Complete elimination by dilatation and omeprazole in H2-blocker refractory cases].
    Koop H; Katschinski M; Arnold R
    Med Klin (Munich); 1991 Nov; 86(11):566-8. PubMed ID: 1685214
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Lansoprazol ++ : a new proton pump inhibitor].
    Baczek J; Laskowiec G
    Pol Merkur Lekarski; 1998 Jun; 4(24):339-41. PubMed ID: 9771021
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.